Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

 Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Shots:

  • Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration
  • Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization activities for the products using the novel capsids
  • The collaboration leverages Dyno’s CapsidMap platform for the development of next-generation AAV vectors for CNS diseases and liver-directed therapies for the portfolio of both Roche and Spark

    Click here to­ read the full press release/ article | Ref: Dyno Therapeutics | Image: Oncology Nurse Advisor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post